Skip to content

Pinteon Therapeutics

2 viewers · 30d

Total raised

$29.2M

1 filing since 2022 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $29.2M
ROUNDS
1
INVESTORS
2
FOUNDED
N/A
HQ
Newton Centre, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Pinteon Therapeutics is a clinical-stage biotechnology company in Newton, Massachusetts developing antibody therapeutics for neurodegenerative disease. Its work centers on cis-pT231 tau, a conformation of the tau protein that is acutely neurotoxic and drives the initiation and spread of tau pathology. The company's lead asset, PNT001, is a monoclonal antibody that has completed a Phase 1 single-ascending-dose study in healthy volunteers and is aimed at tauopathies including traumatic brain injury, chronic traumatic encephalopathy, Alzheimer's disease and progressive supranuclear palsy. Pinteon is a small private company that has raised roughly $52M to date.

What sets it apart

PNT001 is described as the only antibody in development that targets cis-pT231 tau specifically, a conformation-selective epitope that lets it neutralize an acutely neurotoxic form of tau rather than binding total tau, which is intended to both blunt acute neurotoxicity and block the propagation of tau pathology between neurons.

Funding history

1 round
EquityJan 7, 2022
Form D/A
+$29.2M$29.2M total

Latest SEC filings

via EDGAR · CIK 0001613926
Form D/A · Jan 7, 2022View on EDGAR

Products

1 tracked

PNT001

Monoclonal antibody therapeutic

A monoclonal antibody targeting an epitope on cis-pT231 tau, a highly neurotoxic conformation of the tau protein implicated in the initiation and spread of tau pathology in neurodegenerative tauopathies.

  • Conformation-selective binding to cis-pT231 tau rather than total tau
  • Completed Phase 1 single-ascending-dose study in 49 healthy adults at doses from 33 mg to 4,000 mg
  • Well tolerated with no maximum tolerated dose reached and no treatment-related discontinuations
  • Targets multiple tauopathies including traumatic brain injury, chronic traumatic encephalopathy, Alzheimer's disease and progressive supranuclear palsy

Links

WebsiteLinkedInSEC EDGAR filings